Ultrasound contrast developer Acusphere has submitted a new drug application (NDA) to the U.S. Food and Drug Administration for its Imagify ultrasound contrast agent.
Imagify is designed to assess myocardial perfusion, according to the Watertown, MA-based firm.
Related Reading
Acusphere cuts annual net loss, March 17, 2008
Acusphere gets Nasdaq warning letter, January 14, 2008
Acusphere reports Q3 results, November 9, 2007
Acusphere releases Imagify study data, November 6, 2007
Acusphere names new CFO, October 4, 2007
Copyright © 2008 AuntMinnie.com